Previous close | 117,600.00 |
Open | 117,600.00 |
Bid | 114,500.00 x 0 |
Ask | 114,700.00 x 0 |
Day's range | 113,800.00 - 118,700.00 |
52-week range | 93,000.00 - 131,100.00 |
Volume | |
Avg. volume | 20,136 |
Market cap | 1.3T |
Beta (5Y monthly) | 1.09 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1,500.00 (1.28%) |
Ex-dividend date | 27 Dec 2023 |
1y target est | N/A |
GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug (IND) application for their jointly developed MPSIIIA (Sanfilippo Syndrome Type A) treatment, GC1130A.
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval.
GC Cell, a fully integrated cell therapy pioneer has announced poster presentations from studies of its preclinical study of GL205 (GCC2005), a CD5 CAR-NK targeting malignant T-cell lymphoma, and real-world data for the anticancer immunotherapy drug 'Immuncell-LC' at the AACR Annual Meeting 2024 that will take place in San Diego, California, on April 5-10.